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Abstract
Background: Calcium tartrate tetrahydrate has been reported as the main mineral in urinary stones in rats that
have significant tartrate in their diet, but in humans, there has been only one mention of calcium tartrate stones
in the form of bladder stone, and that case was in Africa.
Case Presentation: Patient is a 34-year-old Caucasian male who presented with typical symptoms of ne-
phrolithiasis. CT abd/pelvis (renal stone protocol) revealed a 2 cm nonobstructing stone of the right renal pelvis.
Patient underwent an uncomplicated right percutaneous nephrolithotomy and was noted to be stone free after
surgery. Stone analysis was difficult with regard to determining composition, but was finally identified as
calcium tartrate tetrahydrate.
Conclusion: This was an unusual case, as this is the first recorded case of a calcium tartrate tetrahydrate outside
of Africa. This type of stone had only been mainly described in rat models with dl-bitartrate in their diet. Our
patient was an otherwise healthy, relatively muscular individual with no obvious source for this stone other than
a vitamin and amino acid supplement that he takes regularly that contains l-carnitine (as tartrate) and choline
(as bitartrate and citrate). The prevalence of this stone type is presently unknown, as stone analysis laboratories
have not had the ability to recognize it. Although a connection between the supplement and stone formation is
conjecture at this time, we believe this necessitates further investigation.
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Introduction and Background
Urolithiasis is a significant clinical issue in both adultsand children and its prevalence has been increasing in
the United States and across the globe over the last few de-
cades. Overall prevalence varies between studies, but may
range from 7% to 13%1 in North America to 15% or more.2
The most common type of urinary stones are made of cal-
cium, specifically calcium oxalate,3 and this is particularly
true in the younger age groups. The increased prevalence of
stones is certainly multifactorial and may be associated with
some lifestyle choices. These choices include poor dietary
habits, such as increased consumption of animal protein (and
decreased fruits and vegetables), and poor fluid intake that
often consists of high sugar beverages.1,2,4 Certain supple-
ments and vitamins may also play a role in increasing the rate
of kidney stones.
In this study, we present a case of urolithiasis that re-
vealed a stone composed of calcium tartrate tetrahydrate,
which could have some association with the use of drink
supplements containing tartrate. This composition of
stone had previously been described mainly in rat models.
An association of urolithiasis and renal failure with a pu-
rified diet consisting of dl-choline bitartrate was noted in
rats by Klurfeld5 and Newland et al.6 The composition of
the stones in these rats was not known until Le Bail et al.7
did the crystal determination, confirming the infrared (IR)
spectrum published by Newland et al. and identifying
the compound as racemic calcium tartrate tetrahydrate,
form II.
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Presentation of Case
The patient is a 34-year-old male who initially presented to
our clinic for evaluation of recurrent passage of kidney
stones. He was initially seen in July 2017 and described the
passage of three stones that he was aware of, in the 2 to
3 months leading up to his presentation. During his initial
encounter, he described typical symptoms of urolithiasis with
primarily right-sided flank pain and intermittent episodes of
gross hematuria. Baseline labs were relatively unremarkable
(white blood cell [WBC] count 8.2, Hb 12.0 and Cr 1.13).
Urinalysis demonstrated 2+ blood, 1+ leukocyte esterase,
negative nitrites, and 3 to 9 red blood cells and WBCs. Urine
culture was negative. Physical examination on presentation
was unremarkable.
CT abdomen/pelvis without contrast (renal calculus pro-
tocol) was done and demonstrated a 2 cm nonobstructing
stone in the right renal pelvis (Fig. 1). The average Houns-
field unit value was noted to be 825. The patient was
scheduled to undergo right percutaneous nephrolithotomy
(PCNL) within 2 weeks of presentation.
Surgery
The PCNL procedure was uneventful. A lower pole access
was established through biplanar fluoroscopy, access was
established on the first try, and the tract was then dilated to
30F using the single step balloon dilation system. Lithotripsy
was then achieved using an ultrasonic lithotripter. The stone
was noted to be hard, but broke without difficulty. A 10F
Cope loop nephrostomy tube was left in the upper pole as a
nephrostomy tube and a 5F ureteral catheter was left down
the ureter to help secure the access. The patient underwent a
repeat CT without contrast (renal calculus protocol) the next
morning. CT demonstrated the nephrostomy tube in appropri-
ate position and no evidence of residual stone. Hospital course
was uncomplicated, right antegrade nephrostogram was done
with the contrast seen to be freely flowing down the ureter and
the bladder, the nephrostomy tube was removed per protocol,
and the patient was discharged on postoperative day 1.
Postoperative Follow-Up
UroRisk profile and a future renal ultrasonography (US) were
ordered. The renal US was done at 3 weeks was unremarkable,
FIG. 1. Preoperative CT abdomen/pelvis (renal stone
protocol).
FIG. 2. Photo of stone specimen on mm paper (top), with
micro-CT image slice (bottom). Micro-CT slice includes
standard specimen composed of pure COM (thick arrow),
and apparent CaOx inclusions in the specimen are indicated
with thin arrow. Arrowheads indicate bulk of specimen,
which was verified by infrared spectroscopy to be calcium
tartrate. CaOx, calcium oxalate; COM, calcium oxalate
monohydrate.
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without evidence of obstruction or shadowing to suggest the
possible recurrence of stone. Patient was stone free and
asymptomatic 10 weeks postoperatively.
Stone Analysis
The initial stone analysis reported the stone was a 100%
metabolite, composed strictly of Ciprofloxacin, but there
was no reason to believe that this was an accurate analysis.
The patient was briefly placed on Levofloxacin 2 days be-
fore and 5 days after surgery as prophylaxis, but he had no
previous history of Ciprofloxacin use. This unusual stone
composition resulted in sending the specimen to the stone
analysis laboratory at Indiana University, where micro-CT
imaging revealed a majority stone material with X-ray at-
tenuation significantly less compared with calcium oxalate
(Fig. 2). The IR spectrum of the specimen did not match any
known spectrum, and a consult was sought with the labo-
ratory at Tenon Hospital in Paris. That laboratory identified
the spectrum as being from calcium tartrate tetrahydrate
(Fig. 3).
History/Exposure
After the finding of calcium tartrate in the stone, a thor-
ough history was obtained. The patient reported no previous
history of stones before the events described, no family his-
tory of stone formation, and no history of urinary tract in-
fection. With regard to stone formation, he admitted to
substantial intake of added salt in his daily diet. The patient
worked as a contractor, but only with nonlead-based paints,
and there was no apparent exposure to heavy metals or ag-
ricultural products. The patient did report drinking ‘‘large
quantities.4 or more scoops’’ of a vitamin and amino acid
supplement energy drink/powder every day. Examination of
the active ingredients of the product showed the presence of
l-carnitine (as tartrate) and choline (as bitartrate and citrate).
Each serving (one scoop) contained 10mg of l-carnitine and
500mg choline, and, as such, our patient was drinking 40+
mg and 2000+ mg per day, respectively, with thus an ap-
parent intake of tartrate in the range of grams per day. Cur-
rently, there is no FDA-established daily value for intake of
any of these substances.
UroRisk profile (24-hour urine study) was largely un-
revealing, and the patient had an appropriate total volume of
urine, 2.97 L, and a pH of 6.5. Specifically, there was no
evidence of hyperuricemia (555mg/day), hypocitraturia
(484mg/day), hyperoxaluria (36mg/day), or hypercalciuria
(218mg/day). Only a mild elevation of urine sodium
(216mEq/day) was present.
Discussion
Calcium tartrate has been reported previously in only a
single person, with data contained only in the tables of an
article describing the composition of stones from the West
African nation of Burkina Faso.8 There are no data in that
article on the single male who had a calcium tartrate stone.
Before this, calcium tartrate stones had been demonstrated
only in rats, in association with tartrate in the diet.5–7 The IR
spectrum found for the patient in our study (Fig. 3) is strik-
ingly similar to that reported by Newland et al. in their rat
study.6 The composition of the stone in rats is conclusively
calcium tartrate tetrahydrate,7 which fits with the presence of
tartrate in the diets that caused such stones.
Our patient was a relatively muscular and fit younger male
with no significant comorbidities, no significant family his-
tory, no known metabolic disorders, and no medications that
would be associated with stone formation. As mentioned in
his history, he also had no significant chemical exposures,
other than the dietary supplement that he took. This supple-
ment contains l-carnitine (as tartrate) and choline (as bitar-
trate and citrate). Although this is conjecture at this point, as
calcium readily binds tartrate, we believe it is reasonable that
our patient was ingesting the offending agent, and it was the
tartrate in his diet that led to his stones.
FIG. 3. FT-IR spectrum from the
stone specimen. FT-IR, Fourier trans-
form infrared.
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Conclusion
We report a 34-year-old male with kidney stones com-
posed mainly of calcium tartrate. The patient reported con-
suming a large amount of tartrate as part of a dietary
supplement, which thus could be the cause of his stones. We
include the IR spectrum of this patient’s stone specimen to
facilitate the identification of this unique form of stone in
other laboratories.
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